-+ 0.00%
-+ 0.00%
-+ 0.00%

NANOVIRICIDES, INC - APPLIED TO ACOREP FOR APPROVAL TO BEGIN PHASE II CLINICAL TRIAL OF NV-387 ORAL GUMMIES AS TREATMENT FOR BUNDIBUGYO EBOLAVIRUS

Reuters·07/22/2026 12:32:21

Please log in to view news